

**PROGRAM
naučnih, stručnih skupova i edukativnih seminara
u 2008. godini**

Organizatori

Društvo medicinskih biohemičara Srbije
Komora biohemičara Srbije
Institut za medicinsku biohemiju
Kliničkog centra Srbije

- maj–jun 2008, Beograd*

International Convention of Quality, YUSQ – 2008

Vrsta skupa: stručni skup, učešće uz kotizaciju, registrovani učesnici dobijaju sertifikat

- 17–21. jun 2008, Beograd

XVI Kongres medicinske biohemije i laboratorijske medicine

Mesto održavanja: Hotel »M«, Beograd
Vrsta skupa: nacionalni kongres, učešće uz kotizaciju, registrovani učesnici dobijaju sertifikat

- 19–20. jun 2008, Beograd

**4th EFCC Symposium for Balkan Region
The Impact of the Pre-analytical Phase on the
Quality of the Laboratory Results**

Mesto održavanja: Hotel »M«, Beograd
Vrsta skupa: međunarodni simpozijum, učešće uz kotizaciju, registrovani učesnici dobijaju sertifikat

- 21–24. septembar 2008, Santorini, Grčka

**4th Santorini Conference Biologie Prospective
»Functional Genomics towards Personalized
Health Care«**

- 28. septembar – 02. oktobar 2008, Brazil

**IFCC – World Lab
FORTALEZA – Brazil
20th International Congress of Clinical and
Laboratory Medicine**

- 9–11. oktobar 2008, Beograd

32. Medipharm – Beogradski sajam

Tema: Novine u laboratorijskoj dijagnostici
Vrsta skupa: stručni skup, učešće bez kotizacije

- 16–18. oktobar 2008, Atina, Grčka

**XVI Meeting of Balkan Clinical Laboratory
Federation & 7th Hellenic Congress of
Clinical Chemistry**

- 4. decembar 2008, Beograd

**Jedanaesta naučna konferencija »Profesor
Ivan Berkeš«**

Vrsta skupa: naučna konferencija, učešće bez kotizacije

DRUŠTVO MEDICINSKIH BIOHEMIČARA SRBIJE

Farmaceutski fakultet
Vojvode Stepe 450
11 221 Beograd

Pristupnicu popuniti štampanim slovima, i zajedno sa kopijom uplatnice dostaviti na navedenu adresu!

**PRISTUPNICA
U ČLANSTVO DMBS**

Ime i prezime: _____ Kategorija članstva: _____

Adresa: _____ REDOVNO ČLANSTVO 2.000,00 din

_____ PRIDRUŽENO ČLANSTVO 20.000,00 din

_____ STUDENTI I PENZIONERI – BESPLATNO

Telefon: _____

Datum: _____ Potpis: _____

Članarina se uplaćuje za tekuću godinu na tekući račun DMBS broj 255-0006390101000-02, Privredna banka Beograd a.d., Beograd i obezbeđuje prijem časopisa »Journal of Medical Biochemistry« kao i svih obaveštenja o aktivnostima Društva medicinskih biohemičara Srbije.

JOURNAL OF MEDICAL BIOCHEMISTRY
je član
Društva biomedicinskih časopisa i biltena SR Jugoslavije



Društvo biomedicinskih časopisa i biltena SR Jugoslavije
Yugoslav Society of Biomedical Journals & Bulletins

Adresa:

Društvo biomedicinskih časopisa i biltena SR Jugoslavije,
Medicinski fakultet, Zavod za farmakologiju, Pregradak 380,
21 000 Novi Sad, Srbija.
Telefon: (021) 22-172; Faks: (021) 615-771

Mailing Address:

Yugoslav Society of Biomedical Journals & Bulletins,
Medical School, Department of Pharmacology, P.O.B. 380,
21 000 Novi Sad, Serbia.
Phone: 381-21-22 172; Fax: 381-21-615 771

INSTRUCTIONS FOR AUTHORS

1. Scope and Policy of the Journal

»Journal of Medical Biochemistry« (JMB) publishes original scientific and specialized articles on all aspects of clinical chemistry, medical biochemistry and related scientific disciplines where chemistry, biochemistry, molecular biology and immunochemistry are dealing with the study of normal and pathologic processes in human beings. All manuscripts are reviewed and, after final decision, are classified in the following categories: a) personal view, b) review articles, c) original papers, d) professional papers, e) preliminary reports, and f) reviews of scientific meetings. There are also different reports and news, book reviews, reports on the activity of the Society of Medical Biochemists of Serbia and IFCC and other related organizations, letters to the editor, and information about innovations, new reagents and instruments in the field of clinical chemistry.

JMB articles appear in English and Serbian. Submission of a manuscript to JMB implies that the work described has not been published before, except in the form of an abstract, thesis or lecture, and is not under consideration for publication elsewhere. It is the responsibility of the corresponding author to ensure that all authors see and approve the manuscript before its submission to JMB. Once the manuscript is accepted, it must not be published elsewhere without the consent of the copyright holders. Manuscripts are accepted on condition of transfer of copyright to JMB. A copyright transfer statement will be sent together with the proofs for proofreading. It should be signed by the corresponding author and returned either by e-mail, fax or regular mail.

The journal conforms to the »Uniform requirements for manuscripts submitted to biomedical journals« (*Ann Int Med* 1982; 96: 766–71; *Can Med Assoc J* 1983; 128: 35–9).

2. Manuscript Submission

All manuscripts should be addressed to:
The Editor, »Journal of Medical Biochemistry«, Department of Medical Biochemistry, University School of Pharmacy, Vojvode Stepe 450, 11221 Belgrade, P.O. Box 146, Serbia.

Each manuscript should be accompanied by a cover letter containing a brief statement describing the novelty and importance of the work submitted. Authors may indicate names of reviewers who they wish to be excluded from reviewing their manuscripts.

3. Authorship

This journal accepts the guidelines on authorship developed by the International Committee of Medical Journal Editors. This requires that each author should have participated sufficiently in the work to take public responsibility for the content. This participation must include: (a)

conception or design, or analysis and interpretation of data, or both; (b) drafting the article or revising it critically for important intellectual content; and (c) final approval of the version to be published. Participating solely in the collection of data does *not* justify authorship.

All elements of an article (a), (b), and (c) above, critical to its main conclusions, must be attributable to at least one author. A paper with corporate (collective) authorship must specify the key persons who were responsible for the article; others who contributed to the work should be recognized or acknowledged separately. The Editors may require authors to justify the assignment of authorship.

4. Review of Manuscripts and Speed of Publication

Papers are independently reviewed by at least two reviewers selected by the Editors. Reviews and original manuscripts are judged by the Editor-in-Chief who decides either to accept (without or with minor modifications), to return to the author for revision, or to reject the manuscript. If reviewers disagree, the Editor-in-Chief may ask for a third independent judgment. After completion of the reviewing process, the Editorial Office sends an appropriate letter to the authors together with the anonymized reviews and editorial comments for the author's consideration. Usually, decisions are reached within four weeks from the submission date. When papers are accepted subject to revision, the revised manuscript must be returned within approx. one month. Revised articles are re-evaluated by the Editor-in-Chief who decides to accept or to submit to a second review. It is the aim of the Journal to publish papers within six months after their receipt by the Editor-in-Chief.

The author will receive first proofs for correction. Manuscripts are not returned.

Direct all correspondence to:

Journal of Medical Biochemistry
Prof. Dr Nada Majkić-Singh
Editor-in-Chief
University School of Pharmacy,
Vojvode Stepe 450, 11221 Belgrade,
P.O. Box 146, Serbia.

5. Preparation of Manuscripts

The complete manuscript, including enclosures, should be sent in two copies (original and a photocopy). Enclosures to the original copy should be prepared according to instructions given in this section.

Manuscripts must be written in clear and concise English or Serbian language. The manuscript should be written in the third person avoiding the passive voice. Please have your text proofread by a native English speaker before you submit it for consideration. Either British or American spelling is acceptable. At the proofreading stage, changes other than correction of printer's errors will be charged to the authors.

Type the manuscript (including table legends, figure legends and references) double-spaced using 12 font size on one page of A4 or 8 1/2 × 11" paper. Number the pages consecutively (with the title page being page 1) and leave 2.5 cm margins on all sides. Avoid footnotes in the text, use parentheses instead. Papers and reviews should usually occupy no more than eight printed pages; short communications, case reports and letters to the editor should not exceed four printed pages. Each full page of printed text corresponds to approximately 1400 words. Allow space for tables and illustrations within the page limit.

Manuscripts should be prepared in accordance with the guidelines below and should be sent either by email or by post: one copy on PC-formatted floppy disk or CD-ROM (together with digital images of any figures) and one printed copy. The electronic copy of the manuscript should be saved as a Word for Windows (.doc) or Rich Text Format (.rtf) file. Manuscripts must be submitted using double line-spaced, unjustified text throughout, with headings and subheadings in bold case (not underlined). Press ENTER only at the end of a paragraph, list entry or heading.

Full length papers and technical reports should have Title Page, Summary, Keywords, List of Abbreviations, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, if available, References, Tables and Figure legends.

Short communications and case reports should be subdivided into Summary, Keywords, List of Abbreviations, and a single section of main text without headings. Experimental procedures should be described in legends to figures or footnotes to tables. Acknowledgements and References should be presented as in full length papers.

Letters to the editor are arranged like short communications but without a Summary.

Title page

The title page should include:

1. Short and informative title.
2. Names of all authors (with one name and forename of each author in full), followed by their affiliations: department, institution, city without postcode, country. If there is more than one institution involved, authors' names should be linked to the appropriate institutions by inserting consecutive numbers in superscript after relevant names. If required, lower case letters, in superscript after the name, should be used to indicate the present address.
3. Full name, mailing address, fax phone number and e-mail address of the corresponding author to whom communications should be sent is typed at the bottom.
4. Running title containing 50 characters or less in length.

Summary, Keywords and a list of non-standard abbreviations

The second page of the manuscript should contain Summary, Keywords and a list of non-standard abbreviations used in text, figures, tables, and figure and table legends.

A summary should be short and clear, typed on a separate sheet, and should contain no more than 200 words. The summary should point to the problem, methods, results and discussion. It must be comprehensible to readers before they have read the paper. Reference citations must not appear in the abstract, abbreviations should be avoided.

A short summary in the Serbian language should be typed on the separate sheet, beginning with a Serbian title. Below the end of English and Serbian summaries provide up to six key words in alphabetical order separated by semi-colon using the entries from Index Medicus for indexing purposes.

Introduction

Introduction should be clear, pointing to the essence of the problem and the purpose of the study. References related to the problem discussed in the manuscript should be cited. Do not include data or conclusions from the work being reported.

Materials and methods

The experimental part should include a description of materials and methods used. If methods are widely known, they should not be described, but only references indicated. If the article deals with a new method or modified method, full description should follow. Methods used in statistical analyses should be indicated. Identify accurately all materials, substances, drugs and chemicals used.

Ethics. When reporting experiments on human subjects, manuscripts must include assurance that informed consent was obtained and that the study was performed in conformance with the Declaration of Helsinki ethical guidelines (<http://ohsr.od.nih.gov/helsinki.php3>) as reflected in *a priori* approval by the local institution's, regional or national, human research review committee. Do not use patients' names, initials, or hospital numbers, especially in any illustrative material. When reporting experiments on animals, indicate whether the national law on the care and use of laboratory animals was followed. Articles which do not give assurance of compliance with these principles will be rejected.

Statistics. Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results. If preparing statistical data for publication, please read the journal's statistical guidelines or standard books. Specify any general computer programme used. When data are summarized in the results section, give the statistical methods used to analyze them.

Results

Results should be precise and clear, statistically processed and expressed according to the International System of Units (SI). Present in logical sequence the data generated using, as appropriate, tables and figures without duplica-

tion. Indicate the nature of data reduction and statistical procedures employed with appropriate references.

Discussion

Results should be discussed and compared to reference results. Conclusions should be drawn on the basis of these comparisons. Indicate the conclusions that may be drawn and place them in the context of a critical appraisal of previous work. Do not repeat in detail data or other material given in the introduction or the results section. Link the conclusions with the goals of the study, but avoid unqualified statements and conclusions not completely supported by your data. Distinguish clearly new information from previous finding, and speculation from fact. Problems arising out of the study may be identified, and relevant hypotheses may be generated.

Acknowledgements

Acknowledgements should be placed at the end of the text. Indicate financial support, gifts, technical assistance, and advice. Names of the funding organizations should be written in full. Obtain written permission from those acknowledged by name.

Units of measurement

The units of measurement when possible must belong to the International System of Units (SI) or be non-SI units accepted for use with the SI (e.g. days, litre). (http://www.bipm.fr/3_SI/si.html)

References

Only essential references should be included. Authors are responsible for verifying them against the original source material. Automatic numbering should be avoided. References are typed on sheets separate from the text and follow the text. Rely upon articles published in primary research journals. Meeting abstracts may be cited only if published in journals. Citations such as »personal communication«, »unpublished data« or »in press« are not accepted. Publications for which no author is apparent may be attributed to the organization from which they originate. Simply omit the name of the author for anonymous journal articles – avoid using »Anonymous«.

References are identified in the text by Arabic numerals in parentheses, and numbered consecutively in the order in which they are mentioned in the text. If one reference is cited several times in the text, the same number is indicated in parentheses. Abbreviations of journals conform to those used in Index Medicus (List of Journals Indexed). List all authors; if the number is seven or more, cite first six names followed by *et al.* Do not use italic font in the reference section. References must be given in the following format:

- Articles:
Pugia MM, Sammer R, Corey P, Lott JA, Anderson L, Gleason S, et al. The uristatin dipstick is useful in distin-

guishing upper respiratory from urinary tract infections. *Clin Chim Acta* 2004; 341: 73–81.

Mizon D, Piva F, Queyrel V, Balduyck M, Hachulla E, Mizon J. Urinary bikunin determination provides insight into proteinase/proteinase inhibitor imbalance in patients with inflammatory diseases. *Clin Chem Lab Med* 2002; 40: 579–86.

- Supplements:
Williams DN. Reducing costs and hospital stay for pneumonia with home intravenous cefotaxime treatment: results with a computerized ambulatory drug delivery system. *Am J Med* 1994; 97: Suppl 2A: 50–5.
- Abstracts:
Henney AM. Chronic plaque or acute rupture? The yin and yang of vascular tissue remodeling [abstract]. *Atherosclerosis* 1997; 134: 111.
- Books and Monographs:
Kahn CR, Weir GC, editors, *Joslin's diabetes mellitus*, 13ed. Philadelphia: Lea and Febiger, 1994: 1068pp.
- Chapters:
Karnofsky DH, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. *Evaluation of chemotherapeutic agents*. New York: Columbia University Press, 1949: 191–205.

For more detailed information see CCLM – Guidelines for Authors (*Clin Chem Lab Med* 2005; 43: 108–123).

Tables

Submit tables on separate pages and number them consecutively using Roman numerals. Provide a short descriptive title, column headings, and (if necessary) footnotes to make each table self-explanatory. Refer to tables in the text as Table I, etc. Use Table I, etc. in the table legends. Please indicate in the manuscript the approximate position of each table.

Figures

Illustrations will be reduced in size to fit, whenever possible, the width of a single column, i.e. 80 mm, or a double column, i.e. 168 mm. Ideally, single column figures should be submitted with a width of 100 mm, double column figures with a width of 210 mm. Lettering in all figures within the article should be uniform in style, preferably a sans serif typeface, and of sufficient size, so that it is readable at the final size of approximately 2 mm.

Uppercase letters A, B, C, etc. should be used to identify parts of multi-part figures. Cite all figures in the text in a numerical order. Indicate the approximate position of each figure. Refer to figures in the text as Figure 1, etc. Use Figure 1, etc. in the figure legends.

The first author's name, drawing number and top location are indicated on the back of the illustration.

The number of tables and figures should be rational.

Line drawing and photographs must be of high quality. Note that faint shading may be lost upon reproduction. All illustrations should be black and white and should be numbered in the order in which they are mentioned in the text. The figures must be saved as separate files and printouts appended to the manuscript. All photographic figures should be submitted in camera-ready form (i.e. with all extraneous areas removed) and saved as TIFF files at a resolution of 600 dpi. Line drawings should be professionally prepared and labelled (freehand files). Charts may be supplied as Excel spreadsheets (one chart per sheet). Where necessary, magnification should be shown using a scale marker. The figure legends (one per figure) should appear as a separate page at the end of the main text file. Any previously published illustrations should be accompanied by the written consent to replication of the copyright holder and an acknowledgement should be included in the legend. The full reference should also be included in the reference list.

Figure legends

Provide figure legends on separate pages. Explain all symbols used in the figures. Remember to use the same abbreviations as in text.

Nomenclature

Follow the rules of the IUPAC-IUB Commission on Biochemical Nomenclature, as in IUB *Biochemical Nomenclature and Related Documents*, 3rd edition, obtainable from Biochemical Society Book Depot, P.O. Box 32, and Commerce Way, Colchester, CO2 8HP, U.K.

Enzyme names should be in accordance with the recom-

mendations of the IUPAC-IUB Commission on Biochemical Nomenclature, 1978, as in *Enzyme Nomenclature*, published by Academic Press, New York, 1992. Genotypes should be given in italics, phenotypes should not be italicised. Nomenclature of bacterial genetics should follow Damerec et al. *Genetics* 1966; 54: 61–76.

Abbreviations

JMB accepts standard *Journal of Biological Chemistry* abbreviations. Uncommon abbreviations should be defined, in parentheses, when they first appear in text. Abbreviations in the Title and in the Abstract should be avoided. All non-standard abbreviations should be listed alphabetically on the second page of the manuscript (see above), separated by semicolon. Start with the abbreviation, followed by a comma, and then give the explanation.

Offprints

Page proofs will be sent electronically to the author for correspondence and must be returned promptly by fax or post. The corresponding authors will receive a PDF file of their article. Corrections should be kept to a minimum. This should be completed and returned immediately. The corresponding author will also receive two complimentary copies of the issue in which their article appears.

Please contact the Editorial Office if you have any further questions. We will do our best to assist you.

Please also visit JMB homepage at
<http://www.dmbj.org.yu/jmb>
<http://www.versita.com/science/medicine/jmb>
<http://84.16.249.116/science/medicine/jmb>

STATISTICAL GUIDELINES

These guidelines are designed to help authors prepare statistical data for publication and are not a substitute for the detailed guidance required to design a study or perform a statistical analysis. Each section of a scientific paper is addressed separately.

Summary

The number and source of data must be stated and conclusions which have a statistical basis must be substantiated by inclusion of pertinent descriptive statistics [mean or median, standard deviation (SD) or interquartile range, percentage coefficient of variation (%CV), 95% confidence limits, regression equations, etc.].

Methods

Experimental design, subject selection and randomization procedures should be described and analytical precision quoted when appropriate. The hypotheses to be tested by a statistical procedure must be stated and where appropriate power calculations for the sample size used should be given (it is recommended that the power is <80%). In case-control studies, clearly define how cases and controls were selected and what matching has taken place.

Statistical tests should be described but need not be referenced unless they are unusual or are applied in a non-standard way. Computer software used should be referenced.

If the paper is reporting the results of a diagnostic trial read the STARD statement (1) and for a clinical trial read the CONSORT statement (2) to improve the quality of your report.

Results

Unnecessary precision, particularly in tables, should be avoided. Rounded figures are easier to compare and extra decimal places are rarely important. Descriptive statistics require an additional digit to those used for the raw data. Percentages should not be expressed to more than one decimal place and not be used at all for small samples.

Normally distributed data should be described using a mean, SD and/or %CV and expressed as »mean (SD)« not »mean \pm SD«. When data are not normally distributed, following demonstration by tests such as the Shapiro-Wilk test (3), then medians and interquartile ranges should be used in place of mean and SD. Skewed data can often be normalized by logarithmic transformation or a power transformation. The statistical analysis and calculation of summary statistics should be carried out on the transformed data and the summary statistics transformed back to the original scale for presentation. If a logarithmic scale is used, then graphs should display non-transformed data on a logarithmic scale.

Graphs showing data of comparable magnitude should be of similar size and design. All individual points should be displayed where possible by displacing overlapping points. Error bars showing the standard error of the mean (SEM) or interquartile range, as appropriate, can be used to aid the interpretation of data.

The results of significance tests such as Student's and chi-squared should be presented with descriptive statistics, degrees of freedom (if appropriate) and probability *P*. The validity of any assumptions should be checked (e.g. conventional *t*-tests assume a normal distribution and equal variance for each set of data). For 2 \times 2 contingency table analysis by the chi-squared test the continuity correction must be applied, and for small expected frequencies Fisher's Exact Test used.

P values should be reported in full in 1 or 2 significant figures. Describing *P* values as > 0.05 or NS (not significant) should be avoided. If the results are highly significant and the calculated *P* value from the computer is e.g. 0.000, then the use of *P* < 0.0005 is acceptable. Confidence intervals should be stated, particularly for non-significant results.

The conventional use of statistical significance is $P \leq 0.005$. If a different significance level needs to be used, then the reasons for this must be clearly stated in the statistical method section.

Discussion

Statistical significance should not be equated to importance and *P* values should not be compared between different statistical tests. Association should not be interpreted as causation without additional evidence.

Problem Areas

Multiple comparisons can produce spurious and misleading significance values. The primary hypothesis should always be clearly stated, and associations detected by retrospective analysis should be interpreted with caution. Whenever possible a single overall statistical test should be applied first e.g. ANOVA. If this is not significant, then multiple comparisons must not be applied. If it is significant then some form of multiple range test can be applied. If a single overall test is not possible, then multiple comparisons must use a Bonferroni type significance level.

With paired data the differences between individual pairs of data and the variability of the differences are more important than the individual values. Graphical representation should also show the difference between individual pairs, e.g. by plotted lines joining the paired data points.

Standard regression analysis requires data points to be independent (repeated measurements are not independent). The independent variable should be measurements without significant error, e.g. age or time, and the points should be evenly distributed over the range and have no outliers (this can be easily examined with a scat-

ter plot). These requirements are rarely satisfied with biological data.

Method comparison using regression and correlation coefficients is inappropriate and should be performed using Altman and Bland difference plots (4). If a standard scatter plot and regression line are thought to be useful they can be given along with the Altman – Bland plot. Remember, if two methods are supposed to be measuring the same thing, then it is extremely likely they will be correlated so that a statistical tool correlation not tell you anything new.

If you are carrying out complicated statistical analyses, e.g. multivariate analysis, ROC analysis etc., then it is recommended that you seek advice from a statistician.

References

1. Bossuyt PM, Reitsma JB, Bruns DE, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *Ann Clin Biochem* 2003; 40: 357–63.
2. Moher D, Schultz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomization trials. *Lancet* 2001; 357: 1191–4.
3. Altman DG. *Practical Statistics for Medical Research*. London: Chapman & Hall, 1991: 132–12.
4. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986; 1 (8476): 307–10.

TRANSFER OF COPYRIGHT AGREEMENT STATEMENT

Formal written transfer of copyright from the Author(s) to the publisher is required for each article. Such transfer enables the publisher to provide for the widest possible dissemination of the article through activities such as: irretrievability and accessibility of information; delivery of information; individual article supply; production of microfilm editions; authorization and distribution of reprints; translations; other forms of distribution for the use of all or part of the article in electronic and other formats to be developed. Without this transfer of copyright, such activities on the part of the publisher and the corresponding spread of information are limited; transfer of copyright is also required to enable the publisher to fend off plagiarism and other forms of copyright infringement. We therefore ask that you complete and return this form promptly.

The *Journal of Medical Biochemistry* has adopted the Vancouver criteria for authorship of a scientific paper and before signing this copyright transfer each author must testify him/herself that he/she has made a substantial contribution to the conception and design or analysis and interpretation of data and to drafting the article or revising it critically for important intellectual content and has made the final approval of the version submitted for publication.

Copyright of the article entitled:

to be published in the journal »Journal of Medical Biochemistry« is hereby transferred, throughout the world and the full term and all extensions and renewals thereof, to:

Journal of Medical Biochemistry
Vojvode Stepe 450, 11000 Belgrade, Serbia.

ISSN 1452-8258

I/we am/are willing to accept that my/our name(s) appear(s) as author(s) of the above paper. I/we satisfy the Vancouver criteria for authorship of a manuscript submitted for publication in the *Journal of Medical Biochemistry*.

I/we confirm that the work presented in this paper has not been published or is not currently under consideration for publication elsewhere and that any parts of it which have been presented for a University or other thesis are so acknowledged.

I/we confirm that all reasonable steps have been taken to ensure that no patient referred to in my/our paper can be identified from its contents, and that, where appropriate, consent has been secured from patients to use clinical details relating to them for the purposes of this publication.

I/we confirm that the Ethical Committee approval was sought where necessary and is acknowledged in the text of the paper.

However, the Author(s) reserve(s) the following:

- a) Trademark rights and patent rights, if any;
- b) The right to use all or part of the information contained in this article in future, non-commercial works of the Author's own, or, if the article is a »work-for-hire« and made within the scope of the Author's employment, the employer may use all or part of the information contained in this article for intra-company use, provided the usual acknowledgements are given regarding copyright notice and reference to the original publication.

I/we confirm that, should my/our manuscript be found acceptable for publication, corrected proofs returned by the corresponding author will have been approved by all co-authors.

Signed

.....

.....

.....

It may prove expedient to communicate with the corresponding author directly by telephone, fax or e-mail. Please provide this information below (include the country code).

Corresponding author Tel Fax

E-mail Date

CIP - Katalogizacija u publikaciji
Narodna biblioteka Srbije, Beograd

JOURNAL of Medical Biochemistry : official Journal of the Society of Medical Biochemists of Serbia / editor-in-chief Nada Majkić-Singh. - Štampano izd. - Vol. 27, No. 2 (2008) - Belgrade (Vojvode Stepe 450, P.O. Box 146) : Society of Medical Biochemists of Serbia, Pharmaceutical Faculty, 2008 - ([Belgrade] : Sprint). - 28 cm

Tromesečno. - Je nastavak: Jugoslovenska medicinska biohemija = ISSN 0354-3447. - Drugo izdanje na drugom medijumu: Journal of Medical Biochemistry (Online) = ISSN 1452-8266

ISSN 1452-8258 = Journal of Medical Biochemistry (Štampano izd.)
COBISS.SR-ID 138991884
